Nisar Mah Rukh, Kotha Rudrani, Saad-Omer Sabaa I, Singh Shivani, Olayinka Oluwatoba T, Orelus Jaslin, Yu Ann Kashmer
Neurology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Cureus. 2024 Jul 28;16(7):e65571. doi: 10.7759/cureus.65571. eCollection 2024 Jul.
Migraine causes debilitating headaches and significantly impacts quality of life. Effective migraine-specific treatments have been lacking until the advent of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) receptors, which have expanded therapy options for migraine treatment. This study explores the short- and long-term efficacy and safety of erenumab in migraine treatment. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 criteria guided this systematic review. Five databases - PubMed, PubMed Central, Google Scholar, ScienceDirect, and Sage Journal - were searched for published, freely accessible, full-text articles in English from the past five years. Eligible patients included those with episodic or chronic migraines who received erenumab intervention. From an initial search yielding 680 relevant studies, 12 prospective observational cohort studies were selected after assessing the risk of bias through the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. All included studies demonstrated a significant reduction in monthly migraine days (MMDs) by the end of the treatment period, with mild adverse effects observed. No significant short-term or long-term safety concerns were identified.
偏头痛会导致使人衰弱的头痛，并对生活质量产生重大影响。在靶向降钙素基因相关肽（CGRP）受体的单克隆抗体（mAb）出现之前，一直缺乏有效的偏头痛特异性治疗方法，而这些单克隆抗体扩大了偏头痛治疗的选择范围。本研究探讨了erenumab在偏头痛治疗中的短期和长期疗效及安全性。系统评价和荟萃分析的首选报告项目（PRISMA）2020标准指导了本系统评价。在五个数据库——PubMed、PubMed Central、谷歌学术、ScienceDirect和Sage Journal——中检索了过去五年发表的、可免费获取的英文全文文章。符合条件的患者包括接受erenumab干预的发作性或慢性偏头痛患者。在通过观察性队列和横断面研究质量评估工具评估偏倚风险后，从最初检索到的680项相关研究中选择了12项前瞻性观察性队列研究。所有纳入研究均表明，在治疗期结束时每月偏头痛天数（MMD）显著减少，且观察到轻度不良反应。未发现重大的短期或长期安全问题。
